These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20129378)

  • 1. Lipid apheresis and rheopheresis for treatment of peripheral arterial disease.
    Weiss N
    Atheroscler Suppl; 2009 Dec; 10(5):62-9. PubMed ID: 20129378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical review on the use of lipid apheresis and rheopheresis for treatment of peripheral arterial disease and the diabetic foot syndrome.
    Weiss N
    Semin Dial; 2012; 25(2):220-7. PubMed ID: 22175277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results.
    Weiss N; Julius U
    Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):39-44. PubMed ID: 30875001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indication and implementation of lipidapheresis, rheopheresis, or immunoadsorption (lessons learnt from Germany's largest apheresis center).
    Heigl F; Hettich R; Lotz N; Reeg H; Eder B; Steckholzer-Kroth K; Browatzki M; Harre K; Arendt R
    Atheroscler Suppl; 2009 Dec; 10(5):137-41. PubMed ID: 20129393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apheresis to Mitigate Atherosclerotic Vascular Disease.
    Sachais BS; Shaz BH
    Am J Hypertens; 2018 Jul; 31(8):945-949. PubMed ID: 30016414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of low-density lipoprotein apheresis in the management of peripheral artery disease in patients with chronic kidney disease.
    Tamura K; Tsurumi-Ikeya Y; Wakui H; Maeda A; Ohsawa M; Azushima K; Kanaoka T; Uneda K; Haku S; Azuma K; Mitsuhashi H; Tamura N; Toya Y; Tokita Y; Kokuho T; Umemura S
    Ther Apher Dial; 2013 Apr; 17(2):185-92. PubMed ID: 23551675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shear stress-dependent platelet function after LDL cholesterol apheresis.
    Spieker LE; Ruschitzka F; Badimon JJ; Noll G; Corti R
    Thromb Res; 2004; 113(6):395-8. PubMed ID: 15226094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia.
    Wu MD; Moccetti F; Brown E; Davidson BP; Atkinson T; Belcik JT; Giraud G; Duell PB; Fazio S; Tavori H; Tsimikas S; Lindner JR
    JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 1):1430-1440. PubMed ID: 29909101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and chronic effects of therapeutic apheresis.
    Ramunni A; Petrarulo F; Grasso C; Papagni S; Brescia P
    Atheroscler Suppl; 2013 Jan; 14(1):83-7. PubMed ID: 23357147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single lipid apheresis does not modulate pulse wave reflection in hypercholesterolemic patients.
    Passauer J; Herbrig K; Fischer S; Bornstein S; Julius U
    Atheroscler Suppl; 2009 Dec; 10(5):44-8. PubMed ID: 20129373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia.
    Igarashi K; Tsuji M; Nishimura M; Horimoto M
    J Clin Apher; 2004; 19(1):11-6. PubMed ID: 15095396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients.
    Reimann M; Julius U; Haink K; Lippold B; Tselmin S; Bornstein SR; Reichmann H; Rüdiger H; Ziemssen T
    Atherosclerosis; 2010 Nov; 213(1):212-7. PubMed ID: 20708187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term LDL apheresis does not stably improve hemorheology in hypercholesterolemic patients with coronary artery disease.
    Pusl T; Broedl UC; Parhofer KG; Otto C
    Clin Hemorheol Microcirc; 2009; 41(2):137-42. PubMed ID: 19252236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels.
    Lamounier-Zepter V; Look C; Ehrhart-Bornstein M; Bornstein SR; Fischer S; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):129-34. PubMed ID: 23357154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is lipoprotein (a)-apheresis useful?
    Bambauer R
    Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rheopheresis for sudden sensorineural hearing loss.
    Klingel R; Heibges A; Uygun-Kiehne S; Fassbender C; Mösges R
    Atheroscler Suppl; 2009 Dec; 10(5):102-6. PubMed ID: 20129385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses)].
    Blessing F; Jaeger BR; Oberhoffer M; Reichart B; Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III42-7. PubMed ID: 14663601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of LDL-apheresis on inflammation and microcirculation.
    Koziolek MJ; Mueller GA
    Atheroscler Suppl; 2009 Dec; 10(5):56-8. PubMed ID: 20129376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
    Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S
    Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.